Volition's nu.q® cancer diagnostics test aims to disrupt the multi-billion dollar liquid biopsy industry

Volition study shows rapid, low-cost, automated nu.q® cancer test accurately detects human cancers at high specificity henderson, nev. , march 21, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ('volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated nu.q® cancer immunoassay test in development detected a range of 21 different cancers.
VNRX Ratings Summary
VNRX Quant Ranking